Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
Exelixis (EXEL) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma.” The goal is to see if its drug can help patients whose brain tumors keep growing after standard care, a small but serious niche with few options.
The study tests zanzalintinib, also known as XL092, which is an oral cancer drug taken once a day. It is designed to slow or shrink tumors by blocking signals that drive tumor growth and blood supply.
This is an interventional study where every participant receives the same drug, and there is no placebo or comparison arm. The trial is open label, so both doctors and patients know they are receiving zanzalintinib, and the main aim is to treat the cancer and assess benefit and safety.
The study was first submitted on February 19, 2026, signaling regulatory engagement and trial planning. The most recent update was filed on May 15, 2026, showing the record has been refreshed but enrollment has not yet started.
For investors, this update highlights Exelixis’ push to expand its pipeline beyond its core kidney cancer franchise. Success in a rare brain tumor setting could support a broader label strategy, though near term, the financial impact is limited and sentiment will likely track broader oncology data and moves by rivals.
The study remains in a not-yet-recruiting status and is considered ongoing in setup, with further details available on the ClinicalTrials portal.
To learn more about EXEL’s potential, visit the Exelixis drug pipeline page.
